EUCTR2006-004552-21-FR进行中（未招募）1 期
An open-label, randomized, multi-center, parallel group non-inferiority study of subcutaneous injections of RO0503821 given once monthly vs. darbepoetin alfa given according to local label in patients with chronic kidney disease who are not on dialysis
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 264
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent
- •2. Adults patients (= 18 years old) with CKD stage 3 (creatinine clearance (CrCl)/ Glomerular filtration rate [GFR] 30-59 mL/min) or stage 4 (CrCl/GFR 15-29 mL/min) not requiring dialysis. CrCl/GFR will be estimated at the first screening visit
- •with the Cockcroft-Gault equation or the abbreviated MDRD equation, derived from the full MDRD equation
- •3. Continuous sc maintenance darbepoetin alfa therapy with the same dosing interval (i.e., once a week, once every two weeks or once every month as per local label) for at least 8 weeks before screening and during the screening/baseline period (a maximum of one missed dose in the 12 weeks before randomization in case of weekly administration is allowed).
- •4. Stable sc maintenance darbepoetin alfa therapy during the screening/baseline period (no dose change is allowed)
- •5. Baseline Hb concentration between 10.5 and 13 g/dL (mean of three weekly Hb values determined in week -4, week -2 and visit # 1 before drug administration). Patients with a single Hb value <10.3 g/dL during the screening/baseline period will not be included.
- •6. Stable Hb concentration (defined as any absolute difference of less than or equal 1.2 g/dL between the Hb values measured in week -4, -2 and visit # 1)
- •7. Adequate iron status defined as serum ferritin = 50 ng/mL or TSAT = 15% (or percentage of hypochromic RBCs < 10%) (mean of two values determined in weeks -4 and -2).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Need for dialysis therapy expected in the next 36 weeks or rapid progression of CKD (e.g., a CrCl/GFR decrease of more than 20% within 12 weeks)
- •2. Overt gastrointestinal bleeding within 8 weeks before screening or during the screening/baseline period
- •3. Renal allograft in place
- •4. Immunosuppressive therapy (other than corticosteroids for a chronic condition, cyclosporine, and monoclonal/polyclonal antibodies) in the 12 weeks before the first screening visit or occurring during the screening/baseline period
- •5. RBC transfusions within 8 weeks before screening or during the screening/baseline period
- •6. Hemoglobinopathies (e.g., homozygous sickle-cell disease, thalassemia of all types)
- •7. Hemolysis
- •8. Active malignant disease (except non-melanoma skin cancer). Patients with malignant disease who have been disease-free for at least the 5 previous years are eligible.
- •9. Chronic, uncontrolled or symptomatic inflammatory disease (e.g., rheumatoid arthritis, systemic lupus erythematosus)
- •10. Acute infection requiring antibiotics
- •11. CRP > 15 mg/L
- •12. Vitamin B12 deficiency
- •13. Folic acid deficiency
- •14. Uncontrolled or symptomatic secondary hyperparathyroidism
- •15. Poorly controlled hypertension necessitating interruption of epoetin or darbepoetin alfa treatment in the 6 months before screening
- •16. Epileptic seizure in the 6 months before screening or during the screening/baseline period
- •17. Platelets > 500 x 10 exp9/L
- •18. Pure red cell aplasia (PRCA) or history of PRCA
- •19. Chronic congestive heart failure (New York Heart Association Class IV)
- •20. High likelihood of early withdrawal or interruption of the study (e.g., myocardial infarction, severe or unstable coronary artery disease, stroke, severe liver disease within the 12 weeks before screening or during the screening/baseline period)
- •21. Planned elective surgery during the study period (patients who undergo vascular access surgery, cataract surgery or laser photocoagulation may continue to participate)
- •22. Life expectancy less than 12 months
- •23. Pregnancy or breast-feeding
- •24. Women of childbearing potential without effective contraception
- •25. Previous treatment with RO0503821
- •26. Administration of another investigational drug within 4 weeks
- •before screening or planned during the study period
- •27. Known hypersensitivity to darbepoetin alfa, recombinant human erythropoietin, polyethylene glycol or to any constituent of the study or reference drug formulation
研究者
相似试验
进行中（未招募）
不适用
An open-label, randomized, multi-center, parallel group non-inferiority study of subcutaneous injections of RO0503821 given once monthly vs darbepoetin alfa given according to local label in patients with chronic kidney disease who are not on dialysis - NDChronic renal anemiaMedDRA version: 9.1Level: LLTClassification code 10002073Term: Anaemia of chronic diseaseEUCTR2006-004552-21-ITROCHE264
进行中（未招募）
1 期
An open-label, randomized, multi-center, parallel group non-inferiority study of subcutaneous injections of RO0503821 given once monthly vs. darbepoetin alfa given according to local label in patients with chronic kidney disease who are not on dialysis - SUSTENTOMedDRA version: 8.1Level: LLTClassification code 10058124Term: Nephrogenic anemiaChronic kidney diseaseEUCTR2006-004552-21-GBF. Hoffmann-La Roche Ltd200
进行中（未招募）
不适用
An open-label, randomized, multi-center, parallel group non-inferiority study of subcutaneous injections of RO0503821 given once monthly vs. darbepoetin alfa given according to local label in patients with chronic kidney disease who are not on dialysis - SUSTENTOMedDRA version: 8.1Level: LLTClassification code 10058124Term: Nephrogenic anemiaChronic kidney diseaseEUCTR2006-004552-21-CZF. Hoffmann-La Roche Ltd200
进行中（未招募）
不适用
An open-label, randomized, multi-center, parallel group non-inferiority study of subcutaneous injections of RO0503821 given once monthly vs. darbepoetin alfa given according to local label in patients with chronic kidney disease who are not on dialysis - SUSTENTOChronic kidney diseaseEUCTR2006-004552-21-DEF. Hoffmann-La Roche Ltd200
进行中（未招募）
不适用
An open-label, randomized, multi-center, parallel group non-inferiority study of subcutaneous injections of RO0503821 given once monthly vs. darbepoetin alfa given according to local label in patients with chronic kidney disease who are not on dialysis - STELLATAChronic kidney diseaseEUCTR2006-004552-21-BEF. Hoffmann-La Roche Ltd264